drugset / Trial / NCT07662811
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | 360 mg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | SYHX2011 | Unknown | 260 mg/m2 | Intravenous |
| Comparator | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |